Company intelligence / Profile preview
Hengyi Biomedicine
Shanghai, Chinaibs.fudan.edu.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has an active drug development pipeline with at least two dozen clinical trials ongoing. Specific results or lead asset outcomes are not publicly summarized, but the breadth of activity suggests a robust R&D operation focused primarily on oncology and possibly other therapeutic areas.
No published pivotal results or commercialized drugs identified as of June 2025.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculePeptides
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Hengyi Biomedicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hengyi Biomedicine.